Mezzion Pharma Co.Ltd (140410) — Cash Flow-to-Debt Ratio
Mezzion Pharma Co.Ltd (140410) has a Cash Flow-to-Debt Ratio of -0.07x as of March 2026, meaning its operating cash flow of ₩-6.07 Billion could theoretically repay 0% of its total liabilities (₩83.41 Billion) in one year. Explore Mezzion Pharma Co.Ltd (140410) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mezzion Pharma Co.Ltd Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Mezzion Pharma Co.Ltd across 12 annual periods. Also explore Mezzion Pharma Co.Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Mezzion Pharma Co.Ltd (2012–2025)
Year-by-year debt coverage analysis for Mezzion Pharma Co.Ltd. For market capitalisation and broader financial context, see 140410 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.21x | ₩-16.59 Billion | ₩80.83 Billion | ▲ +69.0% |
| 2024 | -0.66x | ₩-18.49 Billion | ₩27.94 Billion | ▼ -84.4% |
| 2023 | -0.36x | ₩-11.02 Billion | ₩30.70 Billion | ▲ +17.4% |
| 2022 | -0.43x | ₩-12.07 Billion | ₩27.78 Billion | ▲ +39.0% |
| 2021 | -0.71x | ₩-15.07 Billion | ₩21.14 Billion | ▼ -81.8% |
| 2020 | -0.39x | ₩-7.38 Billion | ₩18.82 Billion | ▲ +69.9% |
| 2019 | -1.30x | ₩-20.88 Billion | ₩16.04 Billion | ▼ -6.3% |
| 2018 | -1.22x | ₩-21.72 Billion | ₩17.74 Billion | ▼ -93.4% |
| 2017 | -0.63x | ₩-13.21 Billion | ₩20.87 Billion | ▼ -349.0% |
| 2016 | -0.14x | ₩-6.08 Billion | ₩43.09 Billion | ▼ -422.4% |
| 2015 | 0.04x | ₩1.77 Billion | ₩40.52 Billion | ▼ -94.5% |
| 2012 | 0.79x | ₩3.14 Billion | ₩3.97 Billion | — |